title: A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
abstract: KAF156 belongs to a new class of antimalarial, the imidazolopiperazines, and is currently in clinical development for the treatment of uncomplicated malaria. This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers determined the maximum oral dose of KAF156 tolerated by healthy adults and derived pharmacokinetic data (including preliminary food effect) to enable dose calculations for malaria patients. KAF156 was studied in single-dose cohorts (10 to 1,200 mg, including one 400-mg food effect cohort (4 to 10 subjects/cohort), and in multiple-dose cohorts (60 to 600 mg once daily for 3 days; 8 subjects/cohort). The follow-up period was 6 to 14 days after the last dose. KAF156 was tolerated, with self-limited mild to moderate gastrointestinal and neurological adverse events. In treated subjects after single doses, headache (n = 4; 11.1%), diarrhea (n = 3; 8.3%), dizziness (n = 3; 8.3%), and abdominal pain (n = 2; 5.6%) were the most common adverse events. Headache (n = 4; 16.7%), nausea (n = 3; 12.5%), upper respiratory tract infection (n = 3; 12.5%), and dizziness (n = 2; 8.3%) were the most common adverse events following multiple doses. KAF156 time to maximum concentration (Tmax) was between 1.0 and 6.0 h. Both the area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased more than dose-proportionally in both single- and multiple-ascending-dose cohorts (terminal half-life, 42.5 to 70.7 h). There was no significant accumulation over 3-day repeated administration. The extent of absorption was not significantly affected by food at a single dose of 400 mg, while mean Cmax decreased from 778 ng/ml to 627 ng/ml and Tmax was delayed from a median of 3.0 h under fasting conditions to 6.0 h under fed conditions. Renal elimination is a minor route.
authors.affiliation: Novartis Institute for Tropical Diseases, Singapore joel.leong@novartis.com.
authors.forename: F Joel
authors.initials: FJ
authors.lastname: Leong
authors.affiliation: Novartis Institutes for BioMedical Research, Shanghai, People's Republic of China.
authors.forename: Rong
authors.initials: R
authors.lastname: Zhao
authors.affiliation: Novartis Institutes for BioMedical Research, Shanghai, People's Republic of China.
authors.forename: Shuqi
authors.initials: S
authors.lastname: Zeng
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Baldur
authors.initials: B
authors.lastname: Magnusson
authors.affiliation: Novartis Institute for Tropical Diseases, Singapore.
authors.forename: Thierry T
authors.initials: TT
authors.lastname: Diagana
authors.affiliation: Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Pertel
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000494:pharmacology; D007408:Intestinal Absorption / Q000502:physiology; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000494:pharmacology; D010919:Placebos; D010963:Plasmodium falciparum / Q000187:drug effects; D010966:Plasmodium vivax / Q000187:drug effects; D055815:Young Adult
chemical_list: D000962:Antimalarials; D007093:Imidazoles; D010879:Piperazines; D010919:Placebos; C000599914:ganaplacide